Assumptions in Dose-Response Assessment

TERA has received an investigator-initiated grant from NIEHS and U.S. EPA/Office of Research and Development to write a white paper on research that has impacted the default assumptions used in dose-response assessment. The project Director is Hugh Spitzer, a visiting scientist with TERA, and the Co-Director is Dr. James Wilson of Resources for the Future.

Scientists and risk assessment practitioners were interviewed to determine:

Based on the information collected, the authors, in consultation with an advisory committee, will identify issues for workshops on default assumptions.

Listed below are some of the questions asked of risk assessors. 

  1. Have dose-response assumptions used to characterize the risk associated with cancerous or non-cancerous responses changed or been modified based on new scientific information in the last ten or so years? Can you cite examples of changes?
  2. Has the use of physiologically-based pharmacokinetics and dynamics had a significant impact on the uncertainties associated with low dose extrapolation? Can you cite examples?
  3. What laboratory research is being conducted on generic or chemical specific issues that impact dose-response extrapolation?
  4. What model development is being conducted to improve low-dose extrapolation? What are the plans to test and validate the models?
  5. How would you rank the importance of improving dose-response estimates compared to
    other risk assessment issues?



2300 Montana Avenue, Suite 409, Cincinnati OH 45211
Phone: 513-542-7475
Fax: 513-542-7487

Last updated:  12/03/2010